(PRWEB) May 20, 2011
Synedgen will report recent data from its studies of a new wound rinse at a poster session May 23 at ASM 2011, the annual meeting of the American Society for Microbiology in New Orleans. The poster, Novel Antibacterial Chitosan Derivatives with Residual Activity Reduce Multi-Drug Resistant Biofilms and Remove Bacteria from Abraded Skin, highlights the antibacterial and biofilm-reducing activity of Synedgen’s biopolymer derivative based rinse against a broad spectrum of bacteria. The principal investigator of the study, Synedgen’s Senior Microbiologist Stacy Townsend, will present the results.
Biofilms in wounds are a collection of bacteria that adhere to tissue and create a protective environment that make them nearly impervious to traditional antibiotics. The Synedgen study utilized skin wound models to compare the Synedgen wound rinse against the standard of care. Not only did Synedgen’s chitosan derivatives significantly reduce the number of bacteria in the wound, the rinse demonstrated residual activity after treatment. This residual activity demonstrates that the rinse can remain protective on skin for hours after its use. Testing the product in vitro on bacterial biofilms demonstrated its ability to disrupt the biofilms and to kill the bacteria within.
Cleansing wounds to remove debris and control infection is a key component of wound management. Currently available antiseptic agents can be harmful to human cells and therefore limit wound healing, propelling the need for effective yet non-toxic wound cleaning agents. Synedgen’s wound rinse effectively removes bacteria and biofilms without damaging tissue.
“These results represent a new way of safely treating wounds that have serious infections. The Synedgen technology could be even more useful for chronically infected wounds, removing persistent biofilms and improving outcomes for patients with very few effective options.” remarked Townsend.
Further preclinical studies in vivo are slated for later this year.
Synedgen Inc. is an innovative biopharmaceutical company focused on developing novel therapies and products through its proprietary biomaterials technology platform. This platform technology provides the foundation for environmental and therapeutic antimicrobials to reduce bacterial pathogens. Research is focused to specifically address the unmet need for therapies that treat and prevent bacterial infections, primarily from those that have developed resistance to traditional antibiotics.
Synedgen’s corporate headquarters and research facility is in Claremont, CA; Synedgen’s manufacturing facility is in Honolulu, HI.